PC-Trial: Patent Foramen Ovale and Cryptogenic Embolism
Randomized Clinical Trial Comparing the Efficacy of Percutaneous Closure of Patent Foramen Ovale (PFO) With Medical Treatment in Patients With Cryptogenic Embolism
Sponsor: Abbott Medical Devices
This PHASE4 trial investigates Embolism, Paradoxical and Heart Septal Defects, Atrial and is currently ongoing. Abbott Medical Devices leads this study, which shows 7 recorded versions since 2000 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Unknown PHASE4
-
Sep 2024 — Sep 2025 [monthly]
Unknown PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE4
Status: Unknown Status → Unknown
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status PHASE4
-
Feb 2019 — Jan 2021 [monthly]
Unknown Status PHASE4
▶ Show 2 earlier versions
-
Jun 2018 — Feb 2019 [monthly]
Unknown Status PHASE4
-
Jan 2017 — Jun 2018 [monthly]
Unknown Status PHASE4
First recorded
Feb 2000
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Abbott Medical Devices
- Foundation for Cardiovascular Research, Zurich
For direct contact, visit the study record on ClinicalTrials.gov .